CN102260712B - 溶肿瘤能力增强的B型人腺病毒Ad11突变体的构建和应用 - Google Patents
溶肿瘤能力增强的B型人腺病毒Ad11突变体的构建和应用 Download PDFInfo
- Publication number
- CN102260712B CN102260712B CN2011101433853A CN201110143385A CN102260712B CN 102260712 B CN102260712 B CN 102260712B CN 2011101433853 A CN2011101433853 A CN 2011101433853A CN 201110143385 A CN201110143385 A CN 201110143385A CN 102260712 B CN102260712 B CN 102260712B
- Authority
- CN
- China
- Prior art keywords
- sequence
- gene
- gfp
- pss
- tumor
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 206010028980 Neoplasm Diseases 0.000 title claims abstract description 60
- 241000701161 unidentified adenovirus Species 0.000 title claims abstract description 44
- 238000010276 construction Methods 0.000 title claims abstract description 16
- 210000004881 tumor cell Anatomy 0.000 claims abstract description 43
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 35
- 230000006801 homologous recombination Effects 0.000 claims abstract description 21
- 238000002744 homologous recombination Methods 0.000 claims abstract description 21
- 238000011144 upstream manufacturing Methods 0.000 claims abstract description 14
- 239000013605 shuttle vector Substances 0.000 claims abstract description 12
- 230000014509 gene expression Effects 0.000 claims description 49
- 210000004027 cell Anatomy 0.000 claims description 45
- WIIZWVCIJKGZOK-RKDXNWHRSA-N chloramphenicol Chemical compound ClC(Cl)C(=O)N[C@H](CO)[C@H](O)C1=CC=C([N+]([O-])=O)C=C1 WIIZWVCIJKGZOK-RKDXNWHRSA-N 0.000 claims description 26
- 239000012634 fragment Substances 0.000 claims description 25
- 238000000034 method Methods 0.000 claims description 24
- 108090000790 Enzymes Proteins 0.000 claims description 20
- 102000004190 Enzymes Human genes 0.000 claims description 20
- 229960005091 chloramphenicol Drugs 0.000 claims description 18
- 241000598171 Human adenovirus sp. Species 0.000 claims description 16
- 229960000318 kanamycin Drugs 0.000 claims description 13
- 230000008569 process Effects 0.000 claims description 13
- 241000700605 Viruses Species 0.000 claims description 12
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 claims description 10
- 229940049547 paraxin Drugs 0.000 claims description 8
- 229920001817 Agar Polymers 0.000 claims description 6
- 239000008272 agar Substances 0.000 claims description 6
- 230000029087 digestion Effects 0.000 claims description 6
- 108010048367 enhanced green fluorescent protein Proteins 0.000 claims description 6
- 238000013467 fragmentation Methods 0.000 claims description 6
- 238000006062 fragmentation reaction Methods 0.000 claims description 6
- 239000002773 nucleotide Substances 0.000 claims description 6
- 125000003729 nucleotide group Chemical group 0.000 claims description 6
- 108091008146 restriction endonucleases Proteins 0.000 claims description 6
- 238000001890 transfection Methods 0.000 claims description 6
- 230000003115 biocidal effect Effects 0.000 claims description 4
- 230000008521 reorganization Effects 0.000 claims description 4
- 239000003242 anti bacterial agent Substances 0.000 claims description 3
- 229940088710 antibiotic agent Drugs 0.000 claims description 3
- 238000006073 displacement reaction Methods 0.000 claims description 3
- 229930027917 kanamycin Natural products 0.000 claims description 3
- SBUJHOSQTJFQJX-NOAMYHISSA-N kanamycin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N SBUJHOSQTJFQJX-NOAMYHISSA-N 0.000 claims description 3
- 229930182823 kanamycin A Natural products 0.000 claims description 3
- 108700011259 MicroRNAs Proteins 0.000 claims description 2
- 230000002424 anti-apoptotic effect Effects 0.000 claims description 2
- 238000005516 engineering process Methods 0.000 claims description 2
- 230000001225 therapeutic effect Effects 0.000 claims description 2
- 230000000694 effects Effects 0.000 abstract description 11
- 210000004369 blood Anatomy 0.000 abstract description 9
- 239000008280 blood Substances 0.000 abstract description 9
- 230000004614 tumor growth Effects 0.000 abstract description 7
- 230000017531 blood circulation Effects 0.000 abstract description 2
- 230000002708 enhancing effect Effects 0.000 abstract description 2
- 239000013598 vector Substances 0.000 abstract 6
- 239000003623 enhancer Substances 0.000 abstract 1
- 230000012010 growth Effects 0.000 abstract 1
- 230000000259 anti-tumor effect Effects 0.000 description 9
- 210000005266 circulating tumour cell Anatomy 0.000 description 8
- 230000035945 sensitivity Effects 0.000 description 8
- 108020004999 messenger RNA Proteins 0.000 description 6
- 101000961414 Homo sapiens Membrane cofactor protein Proteins 0.000 description 4
- 102100039373 Membrane cofactor protein Human genes 0.000 description 4
- 201000011510 cancer Diseases 0.000 description 4
- 230000004087 circulation Effects 0.000 description 4
- 238000001514 detection method Methods 0.000 description 4
- 210000000981 epithelium Anatomy 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 241000196324 Embryophyta Species 0.000 description 3
- NTIZESTWPVYFNL-UHFFFAOYSA-N Methyl isobutyl ketone Chemical compound CC(C)CC(C)=O NTIZESTWPVYFNL-UHFFFAOYSA-N 0.000 description 3
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 3
- 230000000735 allogeneic effect Effects 0.000 description 3
- 230000003013 cytotoxicity Effects 0.000 description 3
- 231100000135 cytotoxicity Toxicity 0.000 description 3
- 238000010586 diagram Methods 0.000 description 3
- 231100000304 hepatotoxicity Toxicity 0.000 description 3
- 238000010820 immunofluorescence microscopy Methods 0.000 description 3
- 208000015181 infectious disease Diseases 0.000 description 3
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 3
- 201000002528 pancreatic cancer Diseases 0.000 description 3
- 208000008443 pancreatic carcinoma Diseases 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 238000007920 subcutaneous administration Methods 0.000 description 3
- 208000005443 Circulating Neoplastic Cells Diseases 0.000 description 2
- 206010019851 Hepatotoxicity Diseases 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- 108010017842 Telomerase Proteins 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 230000022534 cell killing Effects 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 230000007686 hepatotoxicity Effects 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 230000000977 initiatory effect Effects 0.000 description 2
- 230000003472 neutralizing effect Effects 0.000 description 2
- 210000004976 peripheral blood cell Anatomy 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 230000010076 replication Effects 0.000 description 2
- 230000009385 viral infection Effects 0.000 description 2
- 210000002845 virion Anatomy 0.000 description 2
- 208000010370 Adenoviridae Infections Diseases 0.000 description 1
- 206010060931 Adenovirus infection Diseases 0.000 description 1
- 102100025473 Carcinoembryonic antigen-related cell adhesion molecule 6 Human genes 0.000 description 1
- 108010001857 Cell Surface Receptors Proteins 0.000 description 1
- 102000000844 Cell Surface Receptors Human genes 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- 108010014173 Factor X Proteins 0.000 description 1
- 101000914326 Homo sapiens Carcinoembryonic antigen-related cell adhesion molecule 6 Proteins 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 206010067125 Liver injury Diseases 0.000 description 1
- 241000699660 Mus musculus Species 0.000 description 1
- 206010060862 Prostate cancer Diseases 0.000 description 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 1
- 244000191761 Sida cordifolia Species 0.000 description 1
- 108010066342 Virus Receptors Proteins 0.000 description 1
- 102000018265 Virus Receptors Human genes 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 208000011589 adenoviridae infectious disease Diseases 0.000 description 1
- 108010084938 adenovirus receptor Proteins 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 239000000090 biomarker Substances 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000000424 bronchial epithelial cell Anatomy 0.000 description 1
- 244000309466 calf Species 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 210000004081 cilia Anatomy 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 238000005336 cracking Methods 0.000 description 1
- 230000009849 deactivation Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 210000004443 dendritic cell Anatomy 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 208000021045 exocrine pancreatic carcinoma Diseases 0.000 description 1
- 201000010536 head and neck cancer Diseases 0.000 description 1
- 208000014829 head and neck neoplasm Diseases 0.000 description 1
- 231100000753 hepatic injury Toxicity 0.000 description 1
- 230000009610 hypersensitivity Effects 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 238000009169 immunotherapy Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 231100000225 lethality Toxicity 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 210000005229 liver cell Anatomy 0.000 description 1
- 230000007056 liver toxicity Effects 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 238000011580 nude mouse model Methods 0.000 description 1
- 210000005259 peripheral blood Anatomy 0.000 description 1
- 239000011886 peripheral blood Substances 0.000 description 1
- 239000013612 plasmid Substances 0.000 description 1
- 238000004393 prognosis Methods 0.000 description 1
- 238000003753 real-time PCR Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 238000010361 transduction Methods 0.000 description 1
- 230000026683 transduction Effects 0.000 description 1
- 238000011830 transgenic mouse model Methods 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- 238000002255 vaccination Methods 0.000 description 1
- 229960005486 vaccine Drugs 0.000 description 1
- 230000029812 viral genome replication Effects 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/76—Viruses; Subviral particles; Bacteriophages
- A61K35/761—Adenovirus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
- C12N2710/10321—Viruses as such, e.g. new isolates, mutants or their genomic sequences
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
- C12N2710/10332—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
- C12N2710/10341—Use of virus, viral particle or viral elements as a vector
- C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
Abstract
Description
Claims (7)
Priority Applications (7)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2011101433853A CN102260712B (zh) | 2011-05-31 | 2011-05-31 | 溶肿瘤能力增强的B型人腺病毒Ad11突变体的构建和应用 |
JP2014513035A JP5943996B2 (ja) | 2011-05-31 | 2012-02-29 | 腫瘍溶解性強化B型ヒトアデノウイルスAd11突然変異体の構築とその応用 |
EP12792810.9A EP2716764B1 (en) | 2011-05-31 | 2012-02-29 | Construction and application of mutant type b human adenovirus ad11 having enhanced oncolytic power |
PCT/CN2012/071757 WO2012163119A1 (zh) | 2011-05-31 | 2012-02-29 | 溶肿瘤能力增强的B型人腺病毒Ad11突变体的构建和应用 |
US14/093,078 US9315827B2 (en) | 2011-05-31 | 2013-11-29 | Subgroup B recombinant human adenovirus vector, and methods for constructing and for using the same |
US15/098,342 US9932606B2 (en) | 2011-05-31 | 2016-04-14 | Subgroup B recombinant human adenovirus vector, and methods for constructing and for using the same |
US15/904,408 US10294493B2 (en) | 2011-05-31 | 2018-02-25 | Subgroup B recombinant human adenovirus vector, and methods for constructing and for using the same |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2011101433853A CN102260712B (zh) | 2011-05-31 | 2011-05-31 | 溶肿瘤能力增强的B型人腺病毒Ad11突变体的构建和应用 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN102260712A CN102260712A (zh) | 2011-11-30 |
CN102260712B true CN102260712B (zh) | 2013-10-02 |
Family
ID=45007547
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN2011101433853A Active CN102260712B (zh) | 2011-05-31 | 2011-05-31 | 溶肿瘤能力增强的B型人腺病毒Ad11突变体的构建和应用 |
Country Status (5)
Country | Link |
---|---|
US (3) | US9315827B2 (zh) |
EP (1) | EP2716764B1 (zh) |
JP (1) | JP5943996B2 (zh) |
CN (1) | CN102260712B (zh) |
WO (1) | WO2012163119A1 (zh) |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102260712B (zh) * | 2011-05-31 | 2013-10-02 | 北京锤特生物科技有限公司 | 溶肿瘤能力增强的B型人腺病毒Ad11突变体的构建和应用 |
WO2014153204A1 (en) | 2013-03-14 | 2014-09-25 | Salk Institute For Biological Studies | Oncolytic adenovirus compositions |
KR102471633B1 (ko) | 2016-02-23 | 2022-11-25 | 솔크 인스티튜트 포 바이올로지칼 스터디즈 | 바이러스 동역학에 미치는 영향 최소화를 위한 치료용 아데노바이러스의 외인성 유전자 발현 |
CA3013637A1 (en) | 2016-02-23 | 2017-08-31 | Salk Institute For Biological Studies | High throughput assay for measuring adenovirus replication kinetics |
CN106591368A (zh) * | 2016-10-12 | 2017-04-26 | 郑州大学 | 携带il‑15r/il‑15融合基因的b亚群腺病毒11载体及其构建和用途 |
CA3045892A1 (en) | 2016-12-12 | 2018-06-21 | Salk Institute For Biological Studies | Tumor-targeting synthetic adenoviruses and uses thereof |
CN110093323B (zh) * | 2018-01-31 | 2024-01-30 | 上海元宋生物技术有限公司 | 重组溶瘤腺病毒OncoAd-P28GANK-E1A-△E1B及其构建方法和应用 |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2006040330A2 (en) * | 2004-10-13 | 2006-04-20 | Crucell Holland B.V. | Improved adenoviral vectors and uses thereof |
CN101090974A (zh) * | 2004-11-16 | 2007-12-19 | 克鲁塞尔荷兰公司 | 包含重组病毒载体的多价疫苗 |
WO2008107370A1 (en) * | 2007-03-02 | 2008-09-12 | Glaxosmithkline Biologicals S.A. | Novel method and compositions |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2354578T3 (es) * | 1999-05-17 | 2011-03-16 | Crucell Holland B.V. | Adenovirus recombinante humano de serotipo ad26. |
CN102260712B (zh) * | 2011-05-31 | 2013-10-02 | 北京锤特生物科技有限公司 | 溶肿瘤能力增强的B型人腺病毒Ad11突变体的构建和应用 |
-
2011
- 2011-05-31 CN CN2011101433853A patent/CN102260712B/zh active Active
-
2012
- 2012-02-29 EP EP12792810.9A patent/EP2716764B1/en active Active
- 2012-02-29 WO PCT/CN2012/071757 patent/WO2012163119A1/zh unknown
- 2012-02-29 JP JP2014513035A patent/JP5943996B2/ja active Active
-
2013
- 2013-11-29 US US14/093,078 patent/US9315827B2/en active Active
-
2016
- 2016-04-14 US US15/098,342 patent/US9932606B2/en active Active
-
2018
- 2018-02-25 US US15/904,408 patent/US10294493B2/en active Active
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2006040330A2 (en) * | 2004-10-13 | 2006-04-20 | Crucell Holland B.V. | Improved adenoviral vectors and uses thereof |
CN101090974A (zh) * | 2004-11-16 | 2007-12-19 | 克鲁塞尔荷兰公司 | 包含重组病毒载体的多价疫苗 |
WO2008107370A1 (en) * | 2007-03-02 | 2008-09-12 | Glaxosmithkline Biologicals S.A. | Novel method and compositions |
Non-Patent Citations (2)
Title |
---|
刘辉等.携带RGD多肽的嵌合型腺病毒载体AD11-RGD-4C-EGFP的构建及其感染效率的研究.《第二军医大学学报》.1921,第31卷(第02期),178-182. |
携带RGD多肽的嵌合型腺病毒载体AD11-RGD-4C-EGFP的构建及其感染效率的研究;刘辉等;《第二军医大学学报》;19210516;第31卷(第02期);178-182 * |
Also Published As
Publication number | Publication date |
---|---|
US10294493B2 (en) | 2019-05-21 |
US20180187214A1 (en) | 2018-07-05 |
US9932606B2 (en) | 2018-04-03 |
JP2014523236A (ja) | 2014-09-11 |
US20140088180A1 (en) | 2014-03-27 |
CN102260712A (zh) | 2011-11-30 |
EP2716764A1 (en) | 2014-04-09 |
US9315827B2 (en) | 2016-04-19 |
US20160222413A1 (en) | 2016-08-04 |
EP2716764A4 (en) | 2015-01-14 |
JP5943996B2 (ja) | 2016-07-05 |
WO2012163119A1 (zh) | 2012-12-06 |
EP2716764B1 (en) | 2019-05-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN102260712B (zh) | 溶肿瘤能力增强的B型人腺病毒Ad11突变体的构建和应用 | |
Rodríguez-García et al. | Safety and efficacy of VCN-01, an oncolytic adenovirus combining fiber HSG-binding domain replacement with RGD and hyaluronidase expression | |
Wong et al. | Oncolytic viruses for cancer therapy: overcoming the obstacles | |
Ylösmäki et al. | Generation of a conditionally replicating adenovirus based on targeted destruction of E1A mRNA by a cell type-specific MicroRNA | |
Jogler et al. | Replication properties of human adenovirus in vivo and in cultures of primary cells from different animal species | |
US10662441B2 (en) | Viral vector targeting cancer stem cells | |
Wang et al. | A new human DSG2-transgenic mouse model for studying the tropism and pathology of human adenoviruses | |
JP5971599B2 (ja) | 制限増殖型アデノウイルス | |
CN101702918A (zh) | 具有e3-19k蛋白的内质网滞留结构域内突变的腺病毒及其在癌症治疗中的应用 | |
WO1999031261A9 (en) | SELECTIVE KILLING AND DIAGNOSIS OF p53+ NEOPLASTIC CELLS | |
Yan et al. | Developing novel oncolytic adenoviruses through bioselection | |
JP2014523236A5 (zh) | ||
Zhu et al. | Incorporating the survivin promoter in an infectivity enhanced CRAd-analysis of oncolysis and anti-tumor effects in vitro and in vivo | |
Mallam et al. | Efficient gene transfer into retinal cells using adenoviral vectors: dependence on receptor expression | |
Su et al. | Triple-serotype chimeric oncolytic adenovirus exerts multiple synergistic mechanisms against solid tumors | |
Gao et al. | Transient chimeric Ad5/37 fiber enhances NK-92 carrier cell-mediated delivery of oncolytic adenovirus type 5 to tumor cells | |
Chahal et al. | Timely synthesis of the adenovirus type 5 E1B 55-kilodalton protein is required for efficient genome replication in normal human cells | |
CN1655827A (zh) | 腺病毒和编码其的核酸的新应用 | |
CN106318915A (zh) | 重组单纯疱疹病毒HSV‑hTERTp_ICP4_LungCA‑GFP及诊断试剂盒 | |
Gao et al. | A systematic comparison of the anti-tumoural activity and toxicity of the three Adv-TKs | |
Kurihara et al. | Telomerase-specific virotheranostics for human head and neck cancer | |
Bernt et al. | A new type of adenovirus vector that utilizes homologous recombination to achieve tumor-specific replication | |
Wang et al. | Oncolytic virus: A catalyst for the treatment of gastric cancer | |
Han et al. | A novel oncolytic adenovirus selectively silences the expression of tumor-associated STAT3 and exhibits potent antitumoral activity | |
Oh et al. | Establishment and characterization of an in vivo model for Epstein–Barr virus positive gastric carcinoma |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
ASS | Succession or assignment of patent right |
Owner name: BEIJING CHUITE BIOTECHNOLOGY CO., LTD. Free format text: FORMER OWNER: ZHENGZHOU UNIVERSITY Effective date: 20120213 |
|
C41 | Transfer of patent application or patent right or utility model | ||
COR | Change of bibliographic data |
Free format text: CORRECT: ADDRESS; FROM: 450001 ZHENGZHOU, HENAN PROVINCE TO: 102206 CHANGPING, BEIJING |
|
TA01 | Transfer of patent application right |
Effective date of registration: 20120213 Address after: 102206 room A215, Building 29, No. 1, life Garden Road, Beijing, Changping District Applicant after: Zhengzhou University Address before: 450001 Zhengzhou science and Technology Development Zone, Henan, No. 100 science Avenue Applicant before: Zhengzhou University |
|
C14 | Grant of patent or utility model | ||
GR01 | Patent grant |